Literature DB >> 27668232

Preventing or treating anti-EGFR related skin rash with antibiotics?

Fausto Petrelli1, Karen Borgonovo1, Sandro Barni1.   

Abstract

Entities:  

Year:  2016        PMID： 27668232      PMCID： PMC5009023          DOI： 10.21037/atm.2016.07.01

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  9 in total

1.  Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.

Authors:  Mario E Lacouture; Edith P Mitchell; Bilal Piperdi; Madhavan V Pillai; Heather Shearer; Nicholas Iannotti; Feng Xu; Mohamed Yassine
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

2.  Management of epidermal growth factor receptor inhibitor-associated rash: a systematic review.

Authors:  Jacqueline Brown; Yun Su; Dave Nelleson; Pallavi Shankar; Carlos Mayo
Journal:  J Community Support Oncol       Date:  2016-01

Review 3.  The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials.

Authors:  F Petrelli; K Borgonovo; S Barni
Journal:  Target Oncol       Date:  2013-01-16       Impact factor: 4.493

4.  Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.

Authors:  Barbara Melosky; Helen Anderson; Ronald L Burkes; Quincy Chu; Desiree Hao; Vincent Ho; Cheryl Ho; Wendy Lam; Christopher W Lee; Natasha B Leighl; Nevin Murray; Sophie Sun; Robert Winston; Janessa J Laskin
Journal:  J Clin Oncol       Date:  2015-11-16       Impact factor: 44.544

5.  Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation.

Authors:  Francesca Mascia; Valentina Mariani; Giampiero Girolomoni; Saveria Pastore
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

Review 6.  Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials.

Authors:  Fausto Petrelli; Karen Borgonovo; Mary Cabiddu; Veronica Lonati; Sandro Barni
Journal:  Lung Cancer       Date:  2012-07-12       Impact factor: 5.705

Review 7.  Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis.

Authors:  F Petrelli; K Borgonovo; M Cabiddu; A Coinu; M Ghilardi; V Lonati; S Barni
Journal:  Br J Dermatol       Date:  2016-09-30       Impact factor: 9.302

Review 8.  Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or Radiotherapy: Update of the Italian Expert Recommendations.

Authors:  Carmine Pinto; Carlo A Barone; Giampiero Girolomoni; Elvio G Russi; Marco C Merlano; Daris Ferrari; Evaristo Maiello
Journal:  Am J Clin Oncol       Date:  2016-08       Impact factor: 2.339

9.  Epidermal EGFR controls cutaneous host defense and prevents inflammation.

Authors:  Beate M Lichtenberger; Peter A Gerber; Martin Holcmann; Bettina A Buhren; Nicole Amberg; Viktoria Smolle; Holger Schrumpf; Edwin Boelke; Parinaz Ansari; Colin Mackenzie; Andreas Wollenberg; Andreas Kislat; Jens W Fischer; Katharina Röck; Jürgen Harder; Jens M Schröder; Bernhard Homey; Maria Sibilia
Journal:  Sci Transl Med       Date:  2013-08-21       Impact factor: 17.956
  9 in total
  2 in total

1.  Cutaneous Toxicities of Molecular Targeted Therapies.

Authors:  Dana Lucia Stanculeanu; Daniela Zob; Oana Catalina Toma; Bogdan Georgescu; Laura Papagheorghe; Raluca Ioana Mihaila
Journal:  Maedica (Bucur)       Date:  2017-01

Review 2.  Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies.

Authors:  Yanping Li; Ruoqiu Fu; Tingting Jiang; Dongyu Duan; Yuanlin Wu; Chen Li; Ziwei Li; Rui Ni; Li Li; Yao Liu
Journal:  Front Oncol       Date:  2022-02-10       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.